Giles Rachel, Maskens Deborah, Bick Robert, Martinez Robin, Packer Malcolm, Heng Daniel, Larkin James, Bex Axel, Jewett Michael, Jonasch Eric, MacLennan Sara
International Kidney Cancer Coalition, Amsterdam-Duivendrecht, The Netherlands.
Kidney Cancer Canada, Mississauga, ON, Canada.
Eur Urol Open Sci. 2022 Jan 17;37:3-6. doi: 10.1016/j.euros.2021.12.003. eCollection 2022 Mar.
The International Kidney Cancer Coalition (IKCC) is a federation of 46 affiliated patient organisations representing 1.2 million patients worldwide that is committed to reducing the global burden of kidney cancer. A large-scale global survey of patients with renal cell carcinoma (RCC) to capture real-world experiences has never been undertaken. The 35-question survey was designed to identify geographic variations in patient education, experience, awareness, access to care, best practices, quality of life, and unmet psychosocial needs. A total of 1983 responses were recorded from 43 countries in 14 languages. Analysis revealed key findings. (1) At diagnosis, 43% of all respondents had no understanding of their RCC subtype. (2) Shared decision-making remains aspirational: globally, 29% of all patients reported no involvement in their treatment decision, responding "My doctor decided for me". (3) While 96% of respondents reported psychosocial impacts, surprisingly, only 50% disclosed them to their health care team. (4) Lastly, 70% of patients were not asked to participate in a clinical trial, although 90% indicated they would be interested. The survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. The data point to actionable deficits in the fields of clinical trials, psychosocial support, and shared decision-making.
In this brief report, we highlight the key results from the first large-scale global survey of patients with kidney cancer to capture real-world experiences. This survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. We conclude that there is a need for improvement in the fields of clinical trials, psychosocial support, and shared decision-making.
国际肾癌联盟(IKCC)是一个由46个附属患者组织组成的联盟,代表着全球120万患者,致力于减轻全球肾癌负担。此前从未对肾细胞癌(RCC)患者进行过大规模的全球调查以了解实际情况。这项包含35个问题的调查旨在确定患者教育、经历、认知、医疗服务可及性、最佳实践、生活质量以及未满足的心理社会需求方面的地域差异。共收到来自43个国家、14种语言的1983份回复。分析得出了关键结果。(1)在确诊时,43%的受访者不了解自己的RCC亚型。(2)共同决策仍有待实现:在全球范围内,29%的患者表示未参与治疗决策,回答是“我的医生替我做了决定”。(3)虽然96%的受访者报告了心理社会影响,但令人惊讶的是,只有50%向其医疗团队透露了这些情况。(4)最后,70%的患者未被邀请参加临床试验,尽管90%表示他们会感兴趣。该调查反映了不同临床场景下患者的观点,在这些场景中有不同的治疗选择。这些数据指出了临床试验、心理社会支持和共同决策领域中可采取行动加以弥补的不足。
在本简要报告中,我们突出了首次针对肾癌患者进行的大规模全球调查的关键结果,以了解实际情况。该调查反映了不同临床场景下患者的观点,在这些场景中有不同的治疗选择。我们得出结论,临床试验、心理社会支持和共同决策领域需要改进。